This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 97.2 kDa. The protein migrates as 80-95 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>80% as determined by SDS-PAGE.
Delivered as bulk protein in a 0.2 μm filtered solution of 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH7.5 with glycerol as protectant.
This product is not suitable for cell based experiments due to cytotoxicity of DDM.
DDM and CHS are INDISPENSABLE to keep CD133 soluble and active, under no circumastance should you remove DDM and CHS.
DDM/CHS buffer (DC-11) is sold separately and not included in protein, and please contact us if you need the buffer.
If glycerol is not compatible to your application, remove glycerol just before immediate experiment, and NEVER store glycerol-free protein solution.
Contact us for customized product form or formulation.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
The product MUST be stored at -70°C or lower upon receipt;
-70°C for 3 months under sterile conditions.
Human CD133, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 80%.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $650.00
Price(USD) : $2600.00
Price(USD) : $5700.00
ACROBiosystems has developed a series of critical reagents for COVID-19 vaccine development and evaluation,including proteins, antibodies and kits. These featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection.
High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.
ACROBiosystems has developed a serial of high-quality antigen and antibody reagents, including super stable trimeric S protein, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity verified by inactivated virus samples.
ACROBiosystems has developed a series of kit products using its high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
This web search service is supported by Google Inc.